VIP Peptide For Sale

Buy VIP peptide: 10mg listed purchase quantities. Compare live prices across 7 listed vendors with real cost per mg, recorded COA availability and discount codes.

Buy VIP peptide starting at $40.00/purchase from 7 listed vendors. Compare 10mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).

How much does VIP cost per month?

An illustrative VIP cost model works out to about $8.66 per month: Ascension Peptides's listed 10 mg purchase quantity at $40.00 with code WPA, divided into 0.1 mg amounts 5x weekly. This quantity provides 100.0 nominal portions — about 20.0 weeks at the selected cadence, before preparation losses or stability limits — for roughly $2.00 per week or $8.66 per 4.33-week month. Vial count and milligrams per vial must be checked separately. This is illustrative arithmetic combining independently selected lifetime modal inputs, not a verified most-common joint protocol. The amount distribution includes 189 calculator runs; overall cadence comes from 15 separate lifetime frequency responses across amounts. Calculator inputs are not confirmed administration or recommendations.

Use the live cost-per-month card to change nominal purchase quantity, amount, cadence and vendor strategy. Recorded purity can be compared separately; it is not independent verification or a quality guarantee. Confirm package composition and checkout price with the vendor.

About VIP

In clinical trialsAlso known as: Vasoactive Intestinal Peptide · Aviptadil

VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide most often sourced for respiratory, anti-inflammatory, and autonomic research. Its synthetic form, aviptadil, has been studied for pulmonary hypertension and COVID-19 respiratory failure. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]

What to check before you buy VIP:

  • A third-party COA showing ≥98% purity by HPLC plus mass-spec confirmation of the 28-amino-acid sequence.
  • A COA dated within the last 6–12 months that matches the exact vial size and batch — VIP degrades readily, so recent testing matters more than usual.
  • Accurate vial fill matching the label; under-filled or degraded vials are a common failure mode that skews reconstitution math.

Inhaled aviptadil was evaluated in sarcoidosis (Prasse et al., Eur Respir J 2010) with positive bronchoalveolar-lavage cytokine effects but no consistent functional improvement.[3] The NIH-sponsored ACTIV-3b ARDS COVID-19 trial (TESICO) of intravenous aviptadil did not meet its primary endpoint (Wright et al., Lancet Respir Med 2023).[4] Earlier work in erectile dysfunction (Invicorp, fixed combination with phentolamine) is approved in some European markets.

Regulatory: Not FDA-approved as a single agent. Aviptadil (synthetic VIP) was studied in Phase 3 COVID-19 ARDS trials without meeting primary endpoints. Invicorp (aviptadil + phentolamine) is approved for erectile dysfunction in selected European markets. Research-grade material elsewhere.

Read the full mechanism & research breakdown

VIP: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how VIP works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide first isolated by Said and Mutt from porcine small intestine in 1970 as a substance with prolonged peripheral vasodilator activity – hence the name.[1] It belongs to the secretin/glucagon peptide superfamily and acts as a co-transmitter alongside acetylcholine in autonomic and enteric neurons throughout the body. VIP signals through two G-protein-coupled receptors – VPAC1 (densely expressed in vascular smooth muscle, GI tract, and T-lymphocytes) and VPAC2 (densely expressed in alveolar type II pneumocytes, immune cells, and CNS) – both of which couple primarily to Gs and elevate intracellular cAMP.[2] Functionally, this drives pulmonary and systemic vasodilation, surfactant up-regulation in alveolar type II cells, suppression of pro-inflammatory cytokine release from macrophages and T cells, and modulation of GI motility. Aviptadil is the recombinant synthetic form used in clinical trials. Plasma half-life is short (a few minutes intravenously), which is why most clinical work has used either inhalation (for pulmonary indications) or continuous IV infusion (for ARDS).

Active research areas

  • Primary pulmonary hypertension (inhaled, historical)
    Petkov and colleagues reported in J Clin Invest 2003 that inhaled VIP produced measurable acute reductions in pulmonary artery pressure and improvements in mixed-venous oxygen saturation in patients with primary pulmonary hypertension, with chronic dosing producing additional symptomatic and haemodynamic benefit over weeks of treatment.[5] No subsequent pivotal Phase 3 program reached approval.
  • Sarcoidosis (inhaled)
    Prasse and colleagues reported in Am J Respir Crit Care Med 2010 that inhaled VIP reduced bronchoalveolar-lavage inflammatory cytokines (notably TNF-α) in patients with pulmonary sarcoidosis, supporting the anti-inflammatory mechanism, although the trial did not produce consistent improvement in pulmonary-function endpoints.[3]
  • COVID-19 associated ARDS (TESICO, intravenous)
    The NIH-sponsored ACTIV-3b / TESICO Phase 3 trial of intravenous aviptadil plus remdesivir in COVID-19-associated hypoxaemic respiratory failure did not meet its primary endpoint (in-hospital recovery status by day 90), formally ending the COVID-ARDS development path for the molecule.[4]
  • Erectile dysfunction (Invicorp, EU-approved combination)
    Aviptadil in fixed combination with phentolamine (Invicorp) is approved in selected European markets for intracavernosal injection in erectile dysfunction unresponsive to PDE-5 inhibitors – the only currently-approved use of synthetic VIP in any major jurisdiction.
  • Chronic Inflammatory Response Syndrome (Shoemaker protocol, off-label)
    Intranasal aviptadil at low microgram doses is the final step in the multi-step Shoemaker protocol for Chronic Inflammatory Response Syndrome (CIRS), a clinical framework that attributes a cluster of multi-system symptoms to chronic biotoxin exposure (most commonly water-damaged-building mould).[6] Both the CIRS diagnostic framework itself and the VIP step within it are contested – they are not recognised by major medical society guidelines and have not been validated in peer-reviewed randomised trials.
Open questions & leading hypotheses (3)
  • Hypothesis: Inhaled VIP's pulmonary haemodynamic benefit (the Petkov 2003 signal) is real and clinically meaningful, but commercial development stalled for non-efficacy reasons.
    Evidence: The 2003 J Clin Invest data showed acute and chronic haemodynamic improvement on validated endpoints in a notoriously difficult-to-treat disease.[5] Counter-evidence: no successor program has reached Phase 3, no inhaled VIP product is approved for pulmonary hypertension in any major market more than 20 years later, and modern endothelin-receptor antagonists, PDE-5 inhibitors, and prostacyclin analogues have largely defined the standard-of-care landscape – which strongly suggests the practical effect-size or delivery economics did not survive larger-scale evaluation.
  • Hypothesis: TESICO's failure reflects the wrong drug for the wrong endpoint rather than VIP-receptor biology failing in ARDS.
    Evidence: TESICO was an IV aviptadil + remdesivir regimen in late-stage COVID-19 hypoxaemic respiratory failure – a population that had largely failed other therapies and had high baseline mortality.[4] Earlier mechanistic and small open-label work motivated the trial. Counter-evidence: the trial was adequately powered for the primary endpoint and was negative; even if dose, route, and timing might be re-explored, the practical conclusion for current clinical use is that aviptadil is not effective for COVID-19 ARDS at the studied protocol.
  • Hypothesis: Intranasal VIP in the Shoemaker CIRS protocol produces real clinical benefit beyond placebo and natural recovery.
    Evidence: Clinicians using the protocol publish open-label case series and outcome registries reporting symptomatic improvement on cognition, energy, and autonomic measures after months of intranasal aviptadil; the proposed mechanism (VPAC-mediated suppression of innate-immune activation) is biologically plausible.[6] Counter-evidence: no controlled trial has tested intranasal VIP in CIRS, the CIRS diagnostic framework itself is not validated by mainstream consensus criteria, no pharmacokinetic data describe what systemic exposure a 50 µg nasal spray actually produces, and the patient population is unusually susceptible to placebo and regression-to-the-mean effects over multi-month protocols.
What community users report

Anecdotal — not controlled-trial evidence

On r/CIRS, r/MoldlyInteresting, and r/Peptides, VIP is most often discussed in the CIRS context – users following the Shoemaker protocol typically run intranasal aviptadil at 50 µg per spray, escalating from one spray daily up to several sprays four times per day, after completing the prior steps of the protocol (anti-binder therapy, MARCoNS clearance, anti-androgen and anti-VEGF normalisation).[6][7] Reported effects skew toward gradual cognitive clarity, reduced post-exertional malaise, and improved temperature regulation over months of use; some users report immediate flushing, mild headache, or transient blood-pressure drops in the first few days of dosing, consistent with VIP's vasodilator pharmacology. A smaller cohort uses subcutaneous aviptadil for chronic fatigue or long-COVID indications outside the CIRS framework.[8] **These reports are anecdotal and have not been validated in controlled trials.** The CIRS diagnostic framework within which most VIP use occurs is itself not endorsed by mainstream medical society guidelines, and no controlled trial has measured the efficacy of intranasal VIP for any of the symptoms users are targeting.

Sources & references (8)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970;169:1217–1218. · PMID: 5450698 link
  2. [2]Harmar AJ et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 2012;166:4–17. · PMID: 22289055 link
  3. [3]Prasse A et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med 2010;182:540–548. · PMID: 20442436 link
  4. [4]Brown SM et al. Intravenous aviptadil and remdesivir for treatment of COVID-19 associated hypoxaemic respiratory failure (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med 2023. · PMID: 37348524 link
  5. [5]Petkov V et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339–1346. · PMID: 12727925 link
  6. [6]Shoemaker RC. Treatment protocols for Chronic Inflammatory Response Syndrome – VIP nasal-spray off-label use (Surviving Mold practitioner protocol). link
  7. [7]Community report – r/CIRS and r/MoldlyInteresting VIP nasal-spray experience threads (subreddit), accessed May 2026. link
  8. [8]Community report – r/Peptides aviptadil / VIP off-label discussions (subreddit), accessed May 2026. link

What VIP Costs Right Now

WPA currently tracks VIP from 7 distinct vendors. In-stock VIP vials run from $40 to $85 — a 2.1x spread for the same compound. Ascension Peptides holds the lowest sticker price at $40. Normalized to milligrams, VIP costs $4.00/mg to $8.50/mg on this page. The best per-milligram value is the listed 10 mg purchase quantity from Ascension Peptides.

VIP is stocked in a single size: 10 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.

Ranked by true cost per milligram, the VIP listings WPA tracks are: Ascension Peptides — 10mg at $40 ($4.00/mg), COA purity 99.83%; EZ Peptides — 10mg at $52.20 ($5.22/mg), COA purity 99.66%; Ameano Peptides — 10mg at $52.20 ($5.22/mg), COA purity 99.54%; LA Peptides — 10mg at $53.99 ($5.40/mg), COA purity 99.80%; Peptira — 10mg at $75.65 ($7.57/mg), COA purity 99.23%.

VIP COA Coverage Across Tracked Vendors

7 of the 7 tracked VIP listings (100%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 7 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.23% to 99.89%. 6 listings record more VIP in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 10/26.

To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the VIP offer. WPA's listing fields do not establish that a report was independently verified.

VIP Calculator Input Observations

In lifetime VIP calculator inputs, 100mcg is the most frequent entered amount (53 of 189 runs). Separately, 5x/week is the most frequent overall cadence (8 of 15 lifetime frequency responses, across entered amounts). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 10 mg of listed product divided by 0.1 mg gives roughly 100 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.

VIP Discount Codes

7 of the 7 tracked VIP listings carry a WPA researcher discount code. The largest live discount is 50% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.

About VIP

VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide most often sourced for respiratory, anti-inflammatory, and autonomic research. Its synthetic form, aviptadil, has been studied for pulmonary hypertension and COVID-19 respiratory failure. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.

VIP is tracked under the Memory Peptides category on WPA. Its reported half-life is ~1–2 min. Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA-approved as a single agent.

How to Read the VIP Comparison

  • Price per milligram — Every VIP listing is normalized to $4.00/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
  • COA metadata and purity — 7 VIP listings are marked for COA availability, and 7 have a recorded purity value. These fields do not independently verify a report.
  • Stock status — Live in-stock state for each VIP listing, refreshed on a recurring basis.

Frequently Asked Questions: VIP

Is it legal and safe to buy VIP for research?

In the US, VIP is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. Vasoactive intestinal peptide is sold strictly as a research chemical with no approved human use in this form. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 7 VIP listings from 7 vendors.

How do I verify a VIP COA so I'm not getting an underdosed vial?

A Certificate of Analysis (COA) may report tests for a specific VIP batch. Check that the report identifies the compound (actually VIP (vasoactive intestinal peptide), not an underdosed or substituted vial), names the laboratory, describes the test method and result, and matches the offered batch and date — recency matters here because VIP degrades quickly. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For VIP specifically, 7 of 7 tracked listings (100%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 7 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 10/26.

Which VIP vendor should I pick?

There's no single "best" VIP vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. VIP is fragile and degrades fast, so COA recency and proper cold-chain handling outweigh a slightly lower price. 7 vendors currently carry VIP, and Ascension Peptides holds the best true value at $4.00/mg on the 10 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.

How much does VIP cost — and how do I know I'm not overpaying?

Judge VIP by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It most often ships in 5 mg vials, so compare $/mg across those rather than the sticker price on one vial. Tracked VIP listings currently run $4.00/mg to $8.50/mg across 10mg listed purchase quantities (not necessarily single vials). WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.

How much VIP do I need for one full cycle?

In lifetime VIP calculator inputs, 100mcg is the most frequent entered amount (53 of 189 runs). Separately, 5x/week is the most frequent overall cadence (8 of 15 lifetime frequency responses, across entered amounts). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 10 mg purchase quantity by 0.1 mg gives roughly 100 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.

Are discount codes available for VIP?

Participating VIP vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 7 of the 7 tracked VIP listings carry a code right now, the largest worth 50% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.

Where can I compare VIP prices and listing details?

This comparison shows 7 tracked listings for VIP in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.